Navigating and Targeting the Novel Tie2 Signaling Pathway to Improve Vascular Integrity in Retinal Diseases

Author(s)/Faculty: Arshad M. Khanani, MD, MA, FASRS; Caroline R. Baumal, MD, FASRS; Carl J. Danzig, MD, FASRS
Release Date: 10/31/2022Expiration Date: 10/30/2023
Credit Type: CMENumber of Credits: 1
Content Type: ArticleProvider:
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified as playing a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering treatment burden with the need for fewer treatment injections over time.

In this continuing medical education activity, experts in the field examine the role of the Tie2 signaling pathway in the pathophysiology of retinal vascular diseases and assess the latest safety and efficacy of therapies that act on the angiopoietin/Tie2 pathway in patients with retinal vascular diseases.